Insider Activity Monitoring: Allogene Therapeutics Inc. (ALLO)

Allogene Therapeutics Inc. (NASDAQ:ALLO) saw an upside of 5.03% on Monday to $13.79 after adding $0.66. The 5-day average trading volume is 6,151,768 shares of the company’s common stock. It has gained $25.00 in the past week. An average of 2,049,737 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,245,449.

ALLO’s 1-month performance is -48.00% or -$10.82 on its low of $12.90 reached on 10/11/21. The company’s shares have touched a 52-week low of $13.13 and high of $44.92, with the stock’s rally to the 52-week high happening on 03/16/21. YTD, ALLO has lost -47.98% or -$11.32. However, the current price is down -69.30%% from the 52-week high price.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


Insider Transactions

On Oct 01, 10 days have gone by since the last insider trading activity for Allogene Therapeutics Inc. (ALLO). Amado Rafael (EVP of R&D and CMO) most recently sold 11,507 shares at $24.35 per share on Oct 01. This transaction cost the insider $280,185. General Counsel, Bhavnagri Veer, sold 5,000 shares at a price of $24.77 on Sep 15. Then, on Sep 09, Director WITTE OWEN N. sold 5,000 shares at a price of $25.54 per share. This transaction amounted to $127,700.

Valuation Metrics

Allogene Therapeutics Inc. (ALLO) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.57 for the sector.ALLO stock has a beta of 0.00. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 90.27 while the price-to-book (PB) in the most recent quarter is 1.73.

Allogene Therapeutics Inc.’s quick ratio for the period ended June 29 was 13.10, with the current ratio over the same period at 13.10 meaning that ALLO stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.00, while the total debt to equity was 0.00.

Earnings Surprise

For the quarterly period ending June 29 this year, Allogene Therapeutics Inc.’s cash and short-term investments amounted to $364.2 million against total debt of $54.36 million. Net income and sales went down compared to those figures reported in the previous quarter. Analysts expected ALLO to announce -$0.55 per share in earnings in its latest quarter, but it posted -$0.53, representing a 3.60% surprise. EBITDA for the quarter stood at more than -$67.23 million. ALLO stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 102.91 million, with total debt at $54.36 million. Shareholders hold equity totaling $142.18 million

Technical Picture

Let’s look briefly at Allogene Therapeutics Inc. (ALLO) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 08 October was 16.39% to suggest the stock is trending oversold, with historical volatility in this time period at 308.27%.

The stock’s 5-day moving average is $19.94, reflecting a -42.65% or -$10.35 change from its current price. ALLO is currently trading -43.80% above its 20-day SMA, -51.11% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -36.58% and -50.09% respectively.

Stochastic %K and %D was 10.31% and 11.64% and the average true range (ATR) pointed at 2.06. The RSI (14) points at 21.46%, while the 14-day stochastic is at 6.82% with the period’s ATR at 1.75. The stock’s 9-day MACD Oscillator is pointing at -5.07 and -6.42 on the 14-day charts.

Analyst Ratings

In the most recent analyst report for Allogene Therapeutics Inc. (NASDAQ: ALLO), Stifel downgraded it to a Hold rating. They previously had a Buy rating on the stock. Analysts offering their rating for ALLO stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate ALLO as a “sell,”, while 3 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 1 rates the stock as overweight while 14 have offered a “buy” rating.

What is ALLO’s price target for the next 12 months?

Analysts have a consensus price target ranging from a low of $18.00 and a high of $55.00, with their median price target at $38.00. Looking at these predictions, the average price target given by analysts is for Allogene Therapeutics Inc. (ALLO) stock is $37.50.


Please enter your comment!
Please enter your name here


Hot Topics

Related Videos

Related Videos

Related Articles



Download Free eBook For



100% free. stop anytime no spam